1. Home
  2. CYCC vs ZBAI Comparison

CYCC vs ZBAI Comparison

Compare CYCC & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • ZBAI
  • Stock Information
  • Founded
  • CYCC 1992
  • ZBAI 2015
  • Country
  • CYCC Malaysia
  • ZBAI United States
  • Employees
  • CYCC N/A
  • ZBAI N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • CYCC Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • CYCC Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • CYCC 7.8M
  • ZBAI 6.4M
  • IPO Year
  • CYCC N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • CYCC $16.04
  • ZBAI $0.42
  • Analyst Decision
  • CYCC
  • ZBAI
  • Analyst Count
  • CYCC 0
  • ZBAI 0
  • Target Price
  • CYCC N/A
  • ZBAI N/A
  • AVG Volume (30 Days)
  • CYCC 5.3M
  • ZBAI 8.3M
  • Earning Date
  • CYCC 08-13-2025
  • ZBAI 06-06-2025
  • Dividend Yield
  • CYCC N/A
  • ZBAI N/A
  • EPS Growth
  • CYCC N/A
  • ZBAI N/A
  • EPS
  • CYCC N/A
  • ZBAI N/A
  • Revenue
  • CYCC $14,000.00
  • ZBAI $720,000.00
  • Revenue This Year
  • CYCC $137.21
  • ZBAI N/A
  • Revenue Next Year
  • CYCC N/A
  • ZBAI N/A
  • P/E Ratio
  • CYCC N/A
  • ZBAI N/A
  • Revenue Growth
  • CYCC N/A
  • ZBAI 44.00
  • 52 Week Low
  • CYCC $3.08
  • ZBAI $0.27
  • 52 Week High
  • CYCC $597.60
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 60.33
  • ZBAI N/A
  • Support Level
  • CYCC $10.05
  • ZBAI N/A
  • Resistance Level
  • CYCC $19.87
  • ZBAI N/A
  • Average True Range (ATR)
  • CYCC 3.57
  • ZBAI 0.00
  • MACD
  • CYCC 1.99
  • ZBAI 0.00
  • Stochastic Oscillator
  • CYCC 77.07
  • ZBAI 0.00

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: